EUVIMEDEUVIMED entdecken
Open Access

Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors

Manabu Watanabe, Hiroyuki Tsuchie, Hiroyuki Nagasawa, Michio Hongo, Yuji Kasukawa, Daisuke Kudo, Fumihito Kasama, Keita Oya, Takashi Kawaragi, Naohisa Miyakoshi

In Vivo · 2025

DOI: 10.21873/invivo.13995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Manabu Watanabe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; mwatanabe@med.akita-u.ac.jp. Hauptthemen laut MEDLINE: Zoledronic Acid, Bone Neoplasms, Bone Density Conservation Agents, Breast Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Breast cancer frequently metastasizes to the bone, reducing quality of life and survival. Zoledronic acid (ZA), is used to treat bone metastasis; however, differences in efficacy depending on the timing of administration are not clear. This study investigated the effects of different timing of ZA administration in a mouse model of breast cancer bone metastasis. MATERIALS AND METHODS: E0771 cells (1.0×105 cells/10 μl) were injected into the femur of C57BL/6 mice to create a local bone metastasis model. The groups that started ZA administration one week before, at the same time as, one week after, and two weeks after tumor-cell administration were designated as the -1w, 0w, 1w, and 2w groups, respectively. A fifth group that did not receive ZA treatment was created as a control. ZA was administered at a dose of 100 μg/kg, and the same dose was administered once a week from the start of administration. The animals were sacrificed two and five weeks after tumor-cell administration. We evaluated body weight at the time of tumor-cell administration and sacrifice, and after sacrifice, the weight of the affected thigh, tumor volume, and bone destruction rate were determined using micro-computed tomography. Tumor necrosis and tumor growth were measured using histological immunostaining. RESULTS: Five weeks after tumor-cell administration, bone destruction rate was significantly lower in all groups compared to the control group (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zoledronic AcidBone NeoplasmsBone Density Conservation AgentsBreast NeoplasmsAnimalsMiceFemaleDisease Models, AnimalCell Line, TumorX-Ray MicrotomographyTumor BurdenDrug Administration ScheduleDiphosphonatesImidazoles

Stichwörter der Autor:innen

Bone metastasisadministration timingzoledronic acid

Substanzen

Zoledronic AcidBone Density Conservation AgentsDiphosphonatesImidazoles

Autor:innen und Institutionen

  • Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan; mwatanabe@med.akita-u.ac.jp.
  • Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Orthopedic Surgery, Akita Kousei Medical Center, Akita, Japan.
  • Department of Orthopedic Surgery, Oomori Municipal Hospital, Akita, Japan.

Zitieren

APA

Watanabe, M., Tsuchie, H., Nagasawa, H., Hongo, M., Kasukawa, Y., Kudo, D., Kasama, F., Oya, K., Kawaragi, T., & Miyakoshi, N. (2025). Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors. In Vivo. https://doi.org/10.21873/invivo.13995

Vancouver

Watanabe M, Tsuchie H, Nagasawa H, Hongo M, Kasukawa Y, Kudo D, et al. Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors. In Vivo. 2025. doi:10.21873/invivo.13995

BibTeX
@article{Watanabe2025,
  author = {Watanabe, Manabu and Tsuchie, Hiroyuki and Nagasawa, Hiroyuki and Hongo, Michio and Kasukawa, Yuji and Kudo, Daisuke and Kasama, Fumihito and Oya, Keita and Kawaragi, Takashi and Miyakoshi, Naohisa},
  title = {Effect of Zoledronic Acid Administration Timing on Metastatic Bone Tumors},
  journal = {In Vivo},
  year = {2025},
  doi = {10.21873/invivo.13995}
}
Kostenlos starten →